Streetbeat News

Revenues

AGL

DIA

KRE

MPW

NVDA

PBW

PTON

QQQ

SPY

U.S. stocks showed mixed performance on Friday, with the S&P 500 and Nasdaq 100 slightly up, while the Dow Jones and Russell 2000 saw declines. Strong jobs data suggested less likelihood of Federal Reserve rate cuts, but a disappointing ISM Service PMI led to lower Treasury yields and some support for stocks. Sector ETFs varied, with Communication Services up and Real Estate down. Regional banks rose, clean energy fell, and semiconductor stocks rebounded. Peloton surged on TikTok partnership news, Agilon Health plunged on reduced revenue guidance and a JPMorgan downgrade, and Medical Properties dropped after announcing plans to reduce exposure to a tenant.

Portfolio Pulse from Piero Cingari

January 05, 2024 | 7:13 pm

SHAK

Analyst ratings for Shake Shack (NYSE:SHAK) show a mix of opinions, with 9 analysts offering varied ratings over the last quarter. The 12-month price targets have an average of $71.11, with a high of $85.00 and a low of $59.00, reflecting a 1.51% decrease from the previous average. Recent actions include ratings and target adjustments by analysts from firms such as Oppenheimer, HSBC, Raymond James, Truist Securities, Stifel, Barclays, Deutsche Bank, and Morgan Stanley. Shake Shack's financials indicate a solid revenue growth rate of 21.24%, an exceptional net margin of 2.76%, but lower ROE and ROA compared to industry averages, and a healthy debt-to-equity ratio of 1.84.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:00 pm

CTRA

Seven analysts have recently updated their ratings on Coterra Energy (NYSE:CTRA), with an average 12-month price target of $31.29, up from $30.40. The ratings range from bullish to indifferent, with no bearish sentiments. Analysts from B of A Securities, Raymond James, UBS, Citigroup, Truist Securities, and Susquehanna have adjusted their price targets and ratings, reflecting their views on the company's performance and market conditions. Coterra, an independent exploration and production company, has faced a significant revenue decline of -46.19% over the past 3 months but maintains a strong net margin of 23.75%. However, its ROE and ROA are below industry averages, and it has a low debt-to-equity ratio of 0.2.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 7:00 pm

PCVX

PHAT

Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT), raising the price target to $26 from $23 and adding it to the Needham Conviction List. Phathom's stock is expected to perform strongly in 2024 due to the launch of Voquezna in Erosive GERD and its anticipated approval and launch in Non-Erosive GERD (NERD). The analyst projects $55.6 million in Voquezna sales for 2024, which is above the consensus estimate of $46 million. Voquezna is seen as a potential best-in-class acid blocker with significant peak sales potential in various indications. Phathom's cash runway is expected to last through 2026, covering multiple value-driving events. PHAT shares recently traded slightly lower at $8.98.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 6:52 pm

IMCR

H.C. Wainwright analyst Patrick R. Trucchio has reiterated a Buy rating on Immunocore Holdings Plc (NASDAQ:IMCR) with a price target of $90. Immunocore announced upcoming data readouts and expanded its pipeline to include autoimmune diseases. The company has one approved drug, KIMMTRAK, and a broad pipeline in various stages of development. Immunocore is also expanding KIMMTRAK's access globally. The company reported a preliminary cash balance of $443 million as of 4Q23, which is expected to support ongoing initiatives. IMCR shares dropped by 4.92% to $66.25.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 6:47 pm

STNE

StoneCo Ltd. (NASDAQ:STNE) shares rose after announcing it received a Financeira License from the Brazilian Central Bank, allowing it to offer new products like time deposits. The license will help diversify funding sources. StoneCo also secured a $467.5 million revolving securitization facility from the U.S. International Development Finance Corporation last month. The company aims to more than double its profitability in four years, targeting an adjusted net income of R$4.3 billion. StoneCo's stock increased by 3.01% to $17.12.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 6:04 pm

Prosperity Bancshares (NYSE:PB) has received mixed analyst ratings over the last quarter, with 5 bullish and 3 indifferent ratings. Recent updates show analysts adjusting their 12-month price targets, with an average target of $67.00, up from $63.29. The company operates a community bank model in Texas and has seen a -6.47% decline in revenue growth as of September 30, 2023. Despite this, it maintains a high net margin of 41.97% but has a lower than average ROE of 1.6%. Its ROA of 0.28% and a debt-to-equity ratio of 0.6 reflect strong financial performance and conservative debt management.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 6:01 pm

CMA

Comerica (NYSE:CMA) received mixed ratings from 16 financial analysts in the past three months, with an average 12-month price target of $53.03, reflecting an 8.05% increase from the previous target. Analysts' actions include raising, maintaining, and lowering ratings and price targets, indicating varied perspectives on Comerica's performance. The company faces challenges with a revenue decline of -9.04% over 3 months but shows strong financial health with a high net margin of 27.23% and an ROE of 4.99%. However, its ROA and high debt-to-equity ratio suggest areas of concern.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 6:00 pm

FHN

Six analysts have recently updated their ratings on First Horizon (NYSE:FHN), with a mix of bullish and indifferent stances. The average 12-month price target is now $14.42, up 15.36% from the previous $12.50. Analysts from firms like Raymond James and Wells Fargo have raised their price targets, reflecting a positive shift in expectations for FHN's stock performance. Despite this, First Horizon faces challenges with revenue decline, below-average net margin, ROE, and ROA, although it maintains a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 6:00 pm

APA

Analysts have provided diverse opinions on APA (NASDAQ:APA) with 11 analysts offering ratings ranging from bullish to bearish. Over the past quarter, sentiments have shifted, with the current average 12-month price target for APA being $45.64, down 11.38% from the previous $51.50. Analysts from firms like Raymond James, UBS, Wells Fargo, Citigroup, RBC Capital, Piper Sandler, Benchmark, Mizuho, Susquehanna, and Bernstein have adjusted their ratings and price targets, mostly lowering them. APA, an independent exploration and production company, has faced a revenue decline of -20.06% over the past 3 months but has strong profitability indicators such as a net margin of 19.89% and ROE of 51.37%. However, the company has a high debt-to-equity ratio of 5.28, indicating potential financial strain.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 6:00 pm